Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Yokokura, Shigeyuki ^a   Yurimoto, Saki ^a   Matsuoka, Akihito ^a   Imataki, Osamu ^a   Dobashi, Hiroaki ^a   Bandoh, Shuji ^a   Matsunaga, Takuya ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Calmodulin; Cell cycle; Multiple myeloma

Indexed keywords

CALCIUM; CALMODULIN INHIBITOR; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; N (4 AMINOBUTYL) 5 CHLORO 2 NAPSYLAMIDE; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; PROTEIN MCL 1; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; CALMODULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE ARREST; CELL MEMBRANE DEPOLARIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CALCIUM SIGNALING; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM SIGNALING; CALMODULIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964313943     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-882     Document Type: Article

References (39)

1. Caers J, Vandebroek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B, Vanderkerken K: Multiple myeloma-an update on diagnosis and treatment. Eur J Haematol 2008, 81:329-343.
2. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992, 10:334-342.
3. Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6, 633 patients from 27 randomized trials. J Clin Oncol 1998, 16:3832-3842.
4. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wislöff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen HE, Lamvik J, Löfvenberg E, Nesthus I, Rödjer S: Impact on survival of highdose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a populationbased study. Nordic Myeloma Study Group. Blood 2000, 95:7-11.
5. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T, Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network: Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011, 118:1239-1247.
6. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, VISTA Trial Investigators: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
7. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma (009) Study Investigators: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
8. Berchtold MW, Villalobo A: The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer. Biochim Biophys Acta 1843, 2014:398-435.
9. Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, Bergsagel L, Chauhan D, Anderson KC: Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004, 103:1799-1806.
10. John D, Shaughnessy JR, Bart B, Fenghuang Z: Gene expression profiling based identification of genomic signatures of multiple myeloma and uses thereof. Patent No. US 2008/0280779, A1 2008.
11. Schüller HM, Orloff M, Reznik GK: Antiproliferative effects of the Ca2 +/calmodulin antagonist B859-35 and the Ca(2+)-channel blocker verapamil on human lung cancer cell lines. Carcinogenesis 1991, 12:2301-2303.
12. Coticchia CM, Revankar CM, Deb TB, Dickson RB, Johnson MD: Calmodulin modulates Akt activity in human breast cancer cell lines. Breast Cancer Res Treat 2009, 115:545-560.
13. Ahn EY, Pan G, Oh JH, Tytler EM, McDonald JM: The combination of calmodulin antagonists and interferon-gamma induces apoptosis through caspase-dependent and-independent pathways in cholangiocarcinoma cells. Am J Pathol 2003, 163:2053-2063.
14. Dewhurst LO, Gee JW, Rennie IG, MacNeil S: Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br J Cancer 1997, 75:860-868.
15. Ito H, Wang JZ, Shimura K: Inhibition of lung metastasis by a calmodulin antagonist, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), in mice bearing Lewis lung carcinoma. Anticancer Res 1991, 11:249-252.
16. Glassford J, Rabin N, Lam EW, Yong KL: Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells. Br J Haematol 2007, 139:243-254.
17. Juge-Morineau N, Mellerin MP, Francois S, Rapp MJ, Harousseau JL, Amiot M, Bataille R: High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 1995, 91:664-667.
18. Donjerkovic D, Scott DW: Regulation of the G1 phase of the mammalian cell cycle. Cell Res 2000, 10:1-16.
19. Taulés M, Rius E, Talaya D, López-Girona A, Bachs O, Agell N: Calmodulin is essential for cyclin-dependent kinase 4 (Cdk4) activity and nuclear accumulation of cyclin D1-Cdk4 during G1. J Biol Chem 1998, 273:33279-33286.
20. Chen BB, Glasser JR, Coon TA, Zou C, Miller HL, Fenton M, McDyer JF, Boyiadzis M, Mallampalli RK: F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. Blood 2012, 119:3132-3141.
21. Dulic V, Lees E, Reed SI: Association of human cyclin E with a periodic G1-S phase protein kinase. Science 1992, 257:1958-1961.
22. Choi J, Chiang A, Taulier N, Gros R, Pirani A, Husain M: A calmodulinbinding site on cyclin E mediates Ca2 +-sensitive G1/s transitions in vascular smooth muscle cells. Circ Res 2006, 98:1273-1281.
23. Colomer J, López-Girona A, Agell N, Bachs O: Calmodulin regulates the expression of cdks, cyclins and replicative enzymes during proliferative activation of human T lymphocytes. Biochem Biophys Res Commun 1994, 200:306-312.
24. Gartel AL, Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005, 65:3980-3985.
25. Bosch M, Gil J, Bachs O, Agell N: Calmodulin inhibitor W13 induces sustained activation of ERK2 and expression of p21(cip1). J Biol Chem 1998, 273:22145-22150.
26. Chambard JC, Lefloch R, Pouysségur J, Lenormand P: ERK implication in cell cycle regulation. Biochim Biophys Acta 2007, 1773:1299-1310.
27. Sewing A, Wiseman B, Lloyd AC, Land H: High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 1997, 17:5588-5597.
28. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M: Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 1997, 17:5598-5611.
29. Balmanno K, Cook SJ: Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999, 18:3085-3097.
30. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495-516.
31. Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC: Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br J Haematol 2003, 123:869-878.
32. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
33. Hodge DR, Xiao W, Wang LH, Li D, Farrar WL: Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells. Cancer Biol Ther 2004, 3:188-194.
34. Gomez-Bougie P, Bataille R, Amiot M: The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 2004, 34:3156-3164.
35. Jan CR, Tseng CJ: W-7 induces [Ca(2+)](i) increases in Madin-Darby canine kidney (MDCK) cells. J Pharmacol Exp Ther 2000, 292:358-365.
36. Ohkubo S, Nakahata N, Ohizumi Y: ML-7 and W-7 facilitate thromboxane A2-mediated Ca2+ mobilization in rabbit platelets. Eur J Pharmacol 1996, 298:175-183.
37. Wang Z, Li S, Shi Q, Yan R, Liu G, Dai K: Calmodulin antagonists induce platelet apoptosis. Thromb Res 2010, 125:340-350.
38. Duchen MR: Mitochondria and calcium: from cell signalling to cell death. J Physiol 2000, 529:57-68.
39. Katayama N, Nishikawa M, Komada F, Minami N, Shirakawa S: A role for calmodulin in the growth of human hematopoietic progenitor cells. Blood 1990, 75:1446-1454.